CheckMate 358: Phase I/II Evaluation of Nivolumab Monotherapy in Virus-Associated, Recurrent/Metastatic Gynecologic Cancers

June 2-6, 2017; Chicago, Illinois
Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.
Format: Microsoft PowerPoint (.ppt)
File Size: 485 KB
Released: June 4, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Clinical commentary with Shannon N. Westin, MD, MPH, discussing patients’ considerations affecting treatment choices, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Released: September 23, 2021

Podcast episode with expert insights on practice changing data from virtual IGCS 2021 for endometrial, ovarian, cervical cancers, from Clinical Care Options (CCO)

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: September 21, 2021

Virtual presentation by Shannon N. Westin, MD, MPH, on improving health equity for patients with endometrial cancer, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue